

TMEM106B modulates disease severity in genetic frontotemporal dementia phenoconverters

Maurice Pasternak¹ | **Saira S. Mirza**¹ | **Andrew D. Paterson**² | **Carmela Tartaglia**^{3,4,5} | **Sara Mitchell**⁶ | **Sandra E. Black**^{3,7,8,9} | **Morris Freedman**^{3,10} | **David F. Tang-Wai**^{11,12,13} | **Ekaterina Rogaeva**¹⁴ | **David M Cash**¹⁵ | **Martina Bocchetta**¹⁶ | **John van Swieten**¹⁷ | **Robert Laforce Jr.**¹⁸ | **Fabrizio Tagliavini**¹⁹ | **Barbara Borroni**²⁰ | **Daniela Galimberti**^{21,22} | **James B Rowe**^{23,24,25} | **Caroline Graff**^{26,27} | **Elizabeth Finger**²⁸ | **Sandro Sorbi**^{29,30} | **Alexandre de Mendonça**³¹ | **Christopher Butler**^{32,33} | **Alexander Gerhard**^{34,35} | **Raquel Sánchez-Valle**³⁶ | **Fermin Moreno**^{37,38} | **Matthis Synofzik**^{39,40} | **Rik Vandenberghe**^{41,42,43} | **Simon Ducharme**^{44,45} | **Johannes Levin**^{46,47,48} | **Markus Otto**⁴⁹ | **Isabel Santana**^{50,51} | **Jonathan D. Rohrer**⁵² | **Mario Masellis**^{8,53,54} |

GENFI

¹Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada

²The Hospital for Sick Children, Toronto, ON, Canada

³University of Toronto, Toronto, ON, Canada

⁴Memory Clinic, Toronto Western Hospital, University Health Network, Toronto, ON, Canada

⁵University of Toronto Department of Medicine, Toronto, ON, Canada

⁶Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada

⁷Hurvitz Brain Sciences Program, Toronto, ON, Canada

⁸Dr. Sandra E. Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada

⁹Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada

¹⁰Rotman Research Institute, Baycrest Health Sciences, Toronto, ON, Canada

¹¹Department of Medicine, University of Toronto, Toronto, ON, Canada

¹²Krembil Brain Institute, University Health Network (UHN), Toronto, ON, Canada

¹³Rotman Research Institute at Baycrest, Toronto, ON, Canada

¹⁴Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada

¹⁵Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom

¹⁶Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, London, United Kingdom

¹⁷Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands

¹⁸Clinique Interdisciplinaire de mémoire, CHU de Québec - Université Laval, Quebec City, QC, Canada

¹⁹Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Neurologica Carlo Besta, Milan, -, Italy

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2025 The Alzheimer's Association. *Alzheimer's & Dementia* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

2 of 3	Alzheimer's & Dementia[®] THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION	BIOMARKERS
²⁰Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy ²¹Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Neurodegenerative Diseases Unit, Milan, Italy ²²Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy ²³Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom ²⁴Department of Clinical Neurosciences, University of Cambridge, Cambridge, Cambridgeshire, United Kingdom ²⁵Medical Research Council Cognition and Brain Sciences Unit, Cambridge, United Kingdom ²⁶Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, -, Sweden ²⁷Unit for Hereditary Dementia, Theme Inflammation and Aging, Karolinska University Hospital-Solna, Stockholm, Stockholm, Sweden ²⁸University of Western Ontario, London, ON, Canada ²⁹IRCCS Fondazione Don Carlo Gnocchi, Florence, Florence, Italy ³⁰University of Florence, Florence, Florence, Italy ³¹Faculty of Medicine, University of Lisbon, Lisbon, Portugal ³²University of Oxford, Oxford, United Kingdom ³³Department of Brain Sciences, Imperial College London, London, United Kingdom ³⁴Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, -, United Kingdom ³⁵Department of Geriatric Medicine, Klinikum Hochsauerland, Arnsberg, Arnsberg, Germany ³⁶Alzheimer's disease and other cognitive disorders Unit. Hospital Clínic de Barcelona; FRCB-IDIBAPS; University of Barcelona, Barcelona, Spain ³⁷Hospital Universitario Donostia, San Sebastian, Gipuzkoa, Spain ³⁸Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain ³⁹Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany ⁴⁰German Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Tübingen, Germany ⁴¹UZ Leuven, Leuven, Belgium ⁴²Leuven Brain Institute, Leuven, Belgium ⁴³Laboratory for Parkinson Research, Leuven Brain Institute, KU Leuven, Leuven, Belgium ⁴⁴Douglas Mental Health University Institute, Montreal, QC, Canada ⁴⁵McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, QC, Canada ⁴⁶Munich Cluster for Systems Neurology (SyNergy), Munich, Munich, Germany ⁴⁷Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich; German Center for Neurodegenerative Diseases (DZNE), Munich; Munich Cluster of Systems Neurology, Munich, Germany ⁴⁸German Center for Neurodegenerative Diseases (DZNE), Munich, Bavaria, Germany ⁴⁹University Hospital Ulm, Ulm, -, Germany ⁵⁰Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Coimbra, Portugal ⁵¹Neurology Service, Faculty of Medicine, University Hospital of Coimbra (HUC), University of Coimbra, Coimbra, Coimbra, Portugal ⁵²Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, -, United Kingdom ⁵³Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada ⁵⁴Cognitive and Movement Disorders Clinic, Sunnybrook Health Sciences Center, Toronto, ON, Canada	Correspondence	Abstract Background: A common variant within TMEM106B is associated with risk for Frontotemporal Lobar Degeneration-Tar DNA binding Protein-43 (FTLD-TDP). A recent study has shown that the minor allele G of TMEM106B-rs1990622 confers protection against FTLD-TDP in symptomatic mutation carriers through reductions in NfL serum levels, brain atrophy, and cognitive decline. It is unknown whether this protective effect is present in phenoconverters of the disease. Method: We included 518 participants from the GENetic Frontotemporal dementia Initiative (GENFI), which recruits genetic FTD cases and their family members, both carriers and non-carriers of FTD mutations. Of these, 21 were phenoconverters,

209 were non-carrier controls, 70 were presymptomatic and 45 symptomatic C9orf72 carriers, 92 presymptomatic and 29 symptomatic GRN carriers, and 39 presymptomatic and 13 symptomatic MAPT carriers. Effects of interaction between TMEM106B-rs1990622 and phenoconverter status were examined using mixed effects models, with a random effects structure featuring subjects nested within families and fixed effects for age at baseline and sex. Serum neurofilament light chain (NfL) was measured using the Simoa platform. Cognitive assessment included the Mini-Mental State Examination (MMSE), tests of attention, processing speed, executive function, and language, as well as the Cambridge Behavioural Inventory (CBI), with mixed effects also including years of education as a covariate. Brain volumetry was assessed using T1-weighted MRI and these mixed effect models also included additional covariates of total intracranial volume and scanner site.

Result: In phenoconverters, each copy of the protective allele G was associated with a significant reduction in the rate of serum NfL accumulation (-5.33 pg/mL/year; $p = 7.79 \times 10^{-9}$). Structural imaging analyses revealed decreased rates of atrophy in fronto-orbital regions and the insular cortex among protective allele carriers. Cognitive trajectories showed significantly slower decline across multiple domains including general cognition (MMSE; $p = 0.003$), attention and processing speed ($p = 2.2 \times 10^{-4}$), executive function ($p = 2.6 \times 10^{-7}$), language ($p = 2.9 \times 10^{-3}$), and behavioural symptoms as measured by CBI ($p = 9.5 \times 10^{-3}$).

Conclusion: The TMEM106B-rs1990622 protective variant significantly modulates disease progression in genetic FTD phenoconverters across multiple markers, suggesting its potential as a therapeutic target.